Treating Diseases of Aging and Treating Aging as Disease™

Immorta Bio’s technologies aim to provide your own young stem cells and your own enhanced immune cells to deal with cancers or diseases of aging the way your body dealt with them when you were young and healthy.

Conventional therapies are mediocre at best in treating diseases of aging. Immorta Bio’s approach, leveraging your younger body’s own natural mechanisms, aims at not only treating diseases of aging, but also potentially opening a door to significant healthy life extension.

Aging as Disease


Aging is the ultimate risk factor for many diseases, marked by progressive deterioration of organs and tissues and an enhanced risk of disease initiation and progression including cancer, cardiovascular disease, metabolic disorders and neurodegeneration. Conventional treatments for diseases associated with aging often provide only symptomatic relief and fail to address the underlying causes of aging.

Existing stem-cell based solutions have limitations, ranging from the absence of personalized sources of "young" cells capable of replacing aging or senescent cells in various, affected organs to largely targeting only one physiological pathway or molecule. Treating aging itself, rather than just the diseases it causes, offers a comprehensive approach to improving health outcomes, increasing longevity, and extending lifespan.

Platforms

High-Technology Laboratory

Immorta Bio is focused on two primary technology paths that have to date generated three platforms: 

·    Cellular Rejuvenation: This technology has generated two platforms (PPCX and PMSC) of patient-specific “immortal” stem cells from their blood. These stem cells can be differentiated into young cells in unlimited quantity. Introduced into damaged or aged organ they rejuvenate surrounding cells, as well as the whole organ itself. Both platforms are applicable to multiple indications.

·    Senolytic Immunotherapy: The SenoVax™ (SNVX) platform, generated from the patient’s blood and skin punch biopsy, consists of the precision targeted immune cells that enhance the body’s innate ability to self-heal. SenoVax™ is applicable to multiple cancers as well as to organ rejuvenation.  

STEM CELL REVIVIFY™

Stem Cell Revivify™:  rejuvenation of a damaged organ to the healthy state
using Immorta Bio Innovative Solution

Stem Cells Solution
  • PRC (Personalized Regenerative Cells):
    Uniquely Derived
  • PPC (Personalized Progenitor Cells):
    Uniquely Potent
  • pMSC (Personalized Mesenchymal Stem Cells):
    Broadly Therapeutic
  • SC Revivify™ (Stem Cell Revivify):
    Unique Results

Patents

1
63/548725
Systemic Means of Dedifferentiation
2
63/591063
Personalized Regenerative Cells
3
63/599440
Personalized Progenitor Cells
4
63/615296
Genetic Modification of Personalized Regenerative Cells
5
63/599431
Generation of Personalized Mesenchymal Stem Cells Utility
6
63/604864
Treatment of Liver Failure Using Personalized Progenitor Cells and Derivatives Thereof
7
63/604867
Treatment of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes and Derivatives Thereof
8
63/604870
Treatment of Multiple Organ Failure with Autologous Pluripotent Stem Cell Derived Therapies
9
63/615298
Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor Homing Personalized Regenerative Cells
10
18/339135
Enhancement of allograft Quality by postmortem donor regeneration
11
63/548741
Therapeutic Use of Autologous Pluripotent Stem Cell and Differentiated Cell Exosomes
#
Patent Title
Patent No
Priority Date
17
Reduction of Senescent Cell Associated Aging and Pathology
63/673915
Jul 22, 2024
16
Enhancement of Regenerative Activity by Inactivation of Senescent Cells
63/660973
Jun 17, 2024
15
Pluripotent Stem Cell Derived Mesenchymal Stem Cells with Enhanced Immune Modulatory Activity
63/645740
May 10, 2024
14
Treatment of Liver Failure by Hepatogenic Monocytes
63/644449
May 8, 2024
13
Senescent Cell Targeting T Cell Responses by Ex Vivo Generated Antigen Presenting Cells
63/637306
Apr 22, 2024
12
Senescence Vaccine
63/560359
Mar 1, 2024
11
Systemic Means of Dedifferentiation
63/548725
Feb 1, 2024
10
Therapeutic Use of Autologous Pluripotent Stem Cell and Differentiated Cell Exosomes
63/548741
Feb 1, 2024
9
Genetic Modification of Personalized Regenerative Cells
63/615296
Dec 28, 2023
8
Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor Homing Personalized Regenerative Cells
63/615298
Dec 28, 2023
7
Treatment of Liver Failure Using Personalized Progenitor Cells and Derivatives Thereof
63/604864
Nov 30, 2023
6
Treatment of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes and Derivatives Thereof
63/604867
Nov 30, 2023
5
Treatment of Multiple Organ Failure with Autologous Pluripotent Stem Cell Derived Therapies
63/604870
Nov 30, 2023
4
Personalized Progenitor Cells
63/599440
Nov 15, 2023
3
Generation of Personalized Mesenchymal Stem Cells
63/599431
Nov 15, 2023
2
Personalized Regenerative Cells
63/591063
Oct 17, 2023
1
Enhancement of allograft Quality by postmortem donor regeneration
18/339135
Jun 21, 2022
1
Personalized Regenerative Cells
63/591063
2
Genetic Modification ofPersonalized Regenerative Cells
63/615296
3
Personalized Progenitor Cells
63/599440
4
Generation of Personalized Mesenchymal Stem Cells Utility
63/599431
5
Treatment of Liver Failure Using Personalized Progenitor Cells andDerivatives Thereof
63/604864
6
Treatment of Heart Failure Using Pluripotent Stem Cell DerivedCardiomyocytes and Derivatives Thereof
63/604867
7
Treatment of Multiple Organ Failure with Autologous Pluripotent StemCell Derived Therapies
63/604870
8
Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor HomingPersonalized Regenerative Cells
63/615298
9
Enhancement of allograft Quality by postmortem donor regeneration
18/339135

Our Mission

to make aging reversible
Happy and healthy people

Our Mission is to develop efficient and practical technology platforms that can be used in treating Diseases of Aging and Treating Aging as Disease™. We leverage autologous pluripotent stem cells to derive unlimited young Personalized Progenitor Cells (PPC) as the core of Immorta Bio therapeutics pipeline.

Collaboration Opportunities

At Immorta Bio, we maintain exclusive marketing rights for our innovative therapeutic programs and are currently raising funds to advance clinical trials, upgrade lab facilities, and support ongoing research and development for our rejuvenation programs. We seek strategic partnerships to maximize their commercial potential, typically after reaching the proof-of-efficacy stage. Contact us to explore collaboration opportunities.

Contact Us

Management Team

BORIS REZNIK, PHD
Boris Reznik, Ph.D.
Chairman and CEO
More
Thomas Ichim
Thomas Ichim, Ph.D.
President and CSO
More
Vladyslav Bykoriz, MD, Ph.D.
Vladyslav Bykoriz, MD, Ph.D.
Chief Medical Officer
More
Yuri Kaplun
Yuri Kaplun, Ph.D.
Chief Information Officer
More

News and Resources

November 20, 2024

Nature Publication Supports Senolytic Approach for Cancer Treatment

November 3, 2024

Immorta CSO Featured in BioFuture 2024 Longevity Panel

October 29, 2024

Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy

See all news

Careers

Immorta Bio embodies a team-centric ethos, comprising highly devoted and skilled individuals. Our collaborative teams operate synergistically within a dynamic, enjoyable, and creatively fulfilling environment. Upholding principles of high integrity, mutual respect, teamwork, open-mindedness, and scientific excellence, we prioritize recruiting, developing, and retaining individuals possessing the determination and expertise essential for success.

We provide compelling career opportunities for individuals passionate about life extension and dedicated to supporting advancements in the biotechnology field.

View job openings
Join our newsletter to stay up to date on features and releases
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com